Review proposal February 2010: proposal to defer the review
Review of NICE Technology Appraisal Guidance No 91; Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for the treatment of advanced ovarian cancer
Proposal to defer the review
As you may be aware the planned date for review of the above guidance was November 2009.
This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.
The Institute has carried out a search for information relevant to this appraisal, and has found that to the best of its knowledge, no new evidence has been published that would have a material effect on the original guidance. However, we are aware of many ongoing clinical trials for both the existing technologies and the newer technologies. Consequently, we propose that the review of the original guidance be deferred until November 2012, to allow this on-going research to be available to inform a review.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial. Please see appendix A for a full list of the organisations we have contacted.
Please note all comments received will be published on the Institute’s website when a decision has been taken.
This page was last updated: 30 March 2010